A Phase 2 Study of the Effect of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib on Disease Response in Patients With High Risk Smoldering Multiple Myeloma
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Ibrutinib (Primary)
- Indications Smoldering multiple myeloma
- Focus Therapeutic Use
- 31 Mar 2020 Status changed from recruiting to discontinued.
- 22 Mar 2018 Planned End Date changed from 1 Nov 2018 to 1 Dec 2023.
- 22 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2023.